Healthcare & Pharmaceuticals
🟢 SERP-Grounded (Light Telemetry)
Bristol-Myers Squibb
Programmatic AI Search & Model Visibility Audit
Share of Model (SOM)The percentage of time frontier AI models (ChatGPT, Claude, Gemini) recommend this brand for high-intent category queries.
18.9%
+0.8% 30-Day MomentumThe rolling 30-day change in algorithmic Share of Model. Positive momentum indicates increasing AI mindshare.
🧠 Neural Valency:NeutralThe contextual sentiment of the AI's recommendation. 'Dominant' implies strong conviction, while 'Vulnerable' implies the model heavily conditions its recommendation.
Algorithmic Threat Detection
Primary Competitor Threat
Merck & Co.
Competitor Displacement Rate
6.5%
Competitors are displacing Bristol-Myers Squibb in 6.5% of high-intent buyer queries.The frequency at which AI models actively suggest a competitor as a superior alternative to this brand.
Algorithmic Rationale: Emerging competitor therapies in immuno-oncology are gaining significant traction, presenting a direct challenge to BMS's established market position.
Missing AI Citations:High-authority domains (e.g., Reddit, G2) that models cite to justify recommending competitors, where this brand currently lacks presence.
[cancer.org][cancerresearch.uk]⚠️ Identified Vulnerability:Therapeutic Innovation
Primary Threat Identified:Merck & Co.
Target Persona:Oncologists evaluating treatment options
🚨 Threat Velocity:4/10An algorithmic urgency score (1-10) indicating how rapidly competitors are capturing this brand's historical AI search share.
Unlock Full Threat Report (30 Free Credits)